Metabolic markers GAPDH, PKM2, ATP5B and BEC-index in advanced serous ovarian cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1472-6890
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Metabolic markers GAPDH, PKM2, ATP5B and BEC-index in advanced serous ovarian cancer ; volume:13 ; number:1 ; day:19 ; month:11 ; year:2013 ; pages:1-8 ; date:12.2013
BMC clinical pathology ; 13, Heft 1 (19.11.2013), 1-8, 12.2013
- Urheber
-
Hjerpe, Elisabet
- Beteiligte Personen und Organisationen
-
Egyhazi Brage, Suzanne
Carlson, Joseph
Frostvik Stolt, Marianne
Schedvins, Kjell
Johansson, Hemming
Shoshan, Maria
Åvall-Lundqvist, Elisabeth
SpringerLink (Online service)
- DOI
-
10.1186/1472-6890-13-30
- URN
-
urn:nbn:de:1111-2016071636201
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:59 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hjerpe, Elisabet
- Egyhazi Brage, Suzanne
- Carlson, Joseph
- Frostvik Stolt, Marianne
- Schedvins, Kjell
- Johansson, Hemming
- Shoshan, Maria
- Åvall-Lundqvist, Elisabeth
- SpringerLink (Online service)
Ähnliche Objekte (12)
Low-grade Serous Ovarian Carcinoma
Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas
Notch signaling in serous ovarian cancer
CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma
Constraint-based modelling predicts metabolic signatures of low and high-grade serous ovarian cancer
A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors
High serum HTATIP2/TIP30 level in serous ovarian cancer as prognostic or diagnostic marker
Benign serous ovarian tumour: a redefining moment?
A case of synchronous serous ovarian cancer and uterine serous endometrial intraepithelial carcinoma
High EVI1 and PARP1 expression as favourable prognostic markers in high-grade serous ovarian carcinoma
Molecular comparison of pure ovarian fibroma with serous benign ovarian tumours
Hilfsmittel Kartei Bec-Bec
Low-grade Serous Ovarian Carcinoma
Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas
Notch signaling in serous ovarian cancer
CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma
Constraint-based modelling predicts metabolic signatures of low and high-grade serous ovarian cancer
A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors
High serum HTATIP2/TIP30 level in serous ovarian cancer as prognostic or diagnostic marker
Benign serous ovarian tumour: a redefining moment?
A case of synchronous serous ovarian cancer and uterine serous endometrial intraepithelial carcinoma
High EVI1 and PARP1 expression as favourable prognostic markers in high-grade serous ovarian carcinoma
Molecular comparison of pure ovarian fibroma with serous benign ovarian tumours
Hilfsmittel Kartei Bec-Bec
Low-grade Serous Ovarian Carcinoma
Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas
Notch signaling in serous ovarian cancer
CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma
Constraint-based modelling predicts metabolic signatures of low and high-grade serous ovarian cancer
A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors
High serum HTATIP2/TIP30 level in serous ovarian cancer as prognostic or diagnostic marker
Benign serous ovarian tumour: a redefining moment?
A case of synchronous serous ovarian cancer and uterine serous endometrial intraepithelial carcinoma
High EVI1 and PARP1 expression as favourable prognostic markers in high-grade serous ovarian carcinoma
Molecular comparison of pure ovarian fibroma with serous benign ovarian tumours